Khurum Khan

Royal Marsden NHS Foundation Trust

Dr Khan research-active consultant in the Gastrointestinal Unit who contributed significantly to the development and business approval of a new Acute Oncology Service (AOS) at the Sutton site.

His clinical training at the Northern Ireland Cancer Centre and Royal Marsden Hospital provided him with broad exposure to a wide range of clinical problems, therapeutic clinical trials of chemotherapy, targeted agents and immunotherapy in both common and rare cancers.

He gained significant experience in the set-up and running of large multicentre academic and translational studies from the time that he spent in full-time research, which included working as trial physician for phase II/III studies in early and advanced Colorectal Cancer sponsored by the industry and the Royal Marsden Hospital and led to an MD (Res). In collaboration with Professor Cunningham, he secured grant funding from Industry to run an academic phase II study of regorafenib in metastatic refractory colorectal cancer that completed recruitment in 2017. He also wrote a successful application for NIHR portfolio adoption of this study. The findings from this study were published in GUT last year. The other important component of my thesis defining the role of ctDNA in metastatic colorectal cancer was considered practice changing and was published in Cancer Discovery earlier this year.

Within the Royal Marsden Drug Development Unit he also gained useful experience of early phase trials. He has been a member of the Royal Marsden Research Ethics Committee and Drugs and Therapeutics Committee since 2018. He also serves as expert member of Surrey Borders National Research and Ethics Committee since 2016.

He enjoys teaching and has played an active role in improving the educational experience of the junior doctors. He writes questions for MRCP (UK) and Medical Oncology exams since 2014, to ensure his positive contribution towards national teaching.

dont miss

Biomarkers of response and/or resistance to targeted therapies in refractory mCRC

Liquid biopsies capture spatial and temporal heterogeneity underpinning resistance to targeted therapies in various cancers. Dense serial sampling is however needed to predict the time to treatment failure and generate a window of opportunity for intervention.

EVEN MORE SEMINARS

  • Dr. Matthew Prime: Speaking at the Oncology Convention

    Dr. Matthew Prime
    Roche Diagnostics Information Solutions

    Personalized healthcare: Leveraging data to improve patient care through clinical decision support in oncology

  • Odette Woods  <br >  AGSM, PgDipRNCM, RGN: Speaking at the Oncology Convention

    Odette Woods
    AGSM, PgDipRNCM, RGN

    Cancer Hopeline

    Empowering Cancer Patients to Optimal Treatment Outcomes and Prognosis

  • Professor Sun Myint: Speaking at the Oncology Convention

    Professor Sun Myint
    Clatterbridge Cancer Centre (Private Clinic)

    Rectal cancer- Do patients have a choice?

  • Ms Claire Barnard: Speaking at the Oncology Convention

    Ms Claire Barnard
    GenesisCare

    Surface-Guided Radiotherapy and Optimal Breast Cancer Treatment

  • Dr Keith Tsui: Speaking at the Oncology Convention

    Dr Keith Tsui
    Medopad

    Remote Patient Monitoring: Bringing the Hospital into the Home